WCG ACI Clinical, the specialty provider of independent endpoint adjudication and data monitoring committees for clinical trials, has launched the latest iteration of its proprietary AIMS (Adjudication Information Management System) platform. AIMS 4.1 offers users of WCG's endpoint adjudication solutions an enhanced interface and workflow experience.
An Endpoint Adjudication Committee is an independent group of experts that reviews clinical trial data in order to give expert opinions about clinical safety or efficacy events of interest.
Custom-built to streamline the adjudication process, the AIMS web-based platform allows global medical experts to review pre-packaged clinical trial event data and provide their expert assessment, through a single interface.
Unlike other adjudication platforms, the AIMS platform was originally designed with a simple, efficient interface for medical expert users, and helps sponsors enhance trial integrity, reduce variation in important clinical trial events and, ultimately, mitigate risk and improve patient safety in clinical trials.
"WCG ACI Clinical deeply understands expert committees and how to optimize their value in clinical programs. We understand each committee member's time is limited and valuable. That's why we designed AIMS to allow committee members to do what they do best: review global trial data, provide their expert assessments, and increase confidence in endpoint accuracy," explained Jonathan Seltzer, MD, MBA, MA, FACC, Chief Scientific Officer of WCG ACI Clinical.
Clients and committee members beta testing the newest version welcomed the enhancements:
"The latest upgrade is yet another step in WCG ACI Clinical's continuing quest to integrate scientific excellence, best practices and exceptional user experience," said Donald A. Deieso, PhD, Chairman and CEO of WCG. "By bringing together clinical expertise from its 700+ global expert community and adjudication expertise from over two decades of successful program support, WCG ACI Clinical's endpoint adjudication solutions are highly differentiated in the industry-the only model that combines specially trained adjudication staff, proprietary technology, and thoughtfully designed processes in one place."
WCG ACI Clinical's expert committee platform enables clinical development companies of all sizes to:
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.